Successful treatment with Protein C of febrile neutropenia in pediatric patients during cancer therapy
- Resource Type
- Authors
- Valerio Cecinati; Giovanni Carlo Delvecchio; Massimo Grassi; Giampaolo Arcamone; Francesco De Leonardis; Paola Giordano; Domenico De Mattia; Letizia Brescia; Nicola Santoro
- Source
- Immunopharmacology and Immunotoxicology. 31:293-298
- Subject
- Male
medicine.medical_specialty
Neutropenia
Fever
Lymphoma
medicine.medical_treatment
Immunology
Cancer therapy
Antineoplastic Agents
Toxicology
Sepsis
Internal medicine
PROTEIN C CONCENTRATE
medicine
Humans
Immunology and Allergy
Child
Pharmacology
Chemotherapy
Leukemia
business.industry
Cancer
Sarcoma
General Medicine
medicine.disease
Surgery
Treatment Outcome
Child, Preschool
Female
business
Complication
Protein C
Febrile neutropenia
medicine.drug
- Language
- ISSN
- 1532-2513
0892-3973
Febrile Neutropenia (FN) is a complication of chemotherapy in childhood cancer and at the same time secondary deficit of Protein C (PC) is often present during sepsis in children with cancer. In this study we have compared the clinical outcome of two different groups. At the onset of FN during chemotherapy the first group (patients with a secondary deficit of PC) received Protein C Concentrate (PCC) replacement while the other group without PC deficiency received only symptomatic therapies. We report that PC replacement could shorten duration of FN and improve the clinical outcome. The administration of PCC was safe and without any complications.